Normally you would think that having a differentiated and proprietary diabetes compound with solid supporting data would make a biotech relatively popular. That would often be particularly true in cases where the drug class has already proven to be pretty popular with drug companies and started to generate real interest among clinicians.
Unfortunately for Lexicon Pharmaceuticals' (LXRX) shareholders, things aren't going to plan yet. The company's LX4211 remains the only compound I'm aware of that inhibits both SGLT1 and SGLT2 (other drugs just address SGLT2) and the data have been good so far. Yet, another SGLT2 partnership deal has gone off in the space without including Lexicon - forcing investors to wonder whether a good partnership deal...
Only subscribers can access this article, which is part of the PRO research library covering 3,604 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: